Financial Report: Roche 1Q

Roche 1Q

1Q Revenues: $10.1 billion (-1%)

1Q Earnings: n/a*

Comments: Pharmaceutical revenues were flat at $8.1 billion (up 8% in local currencies) with Europe/ROW sales down 8%, U.S. sales up 1%, and Japan sales up 58%. Sales drivers were Avastin, Herceptin, Tamiflu, MabThera/Rituxan and Lucentis. In the U.S., growth of key products offset lower sales of Tamiflu. Sales by Chugai in Japan increased due to Tamiflu, anticancer medicines, and Actemra, which was approved for RA in Japan in April 2008. In local currencies, global sales of Tamiflu were up 38%; Avastin sales were up 30%; Herceptin sales increased 11%; U.S. sales of Lucentis increased 21%; and overall sales of MabThera/Rituxan rose 6%.

*The company reports earnings only for 1H and FY.